Terms: = Kidney tumors AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
440 results:
1. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract] [Full Text] [Related]
2. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and treatment Implications.
Li J; Zhang L; Ge T; Liu J; Wang C; Yu Q
Drug Des Devel Ther; 2024; 18():829-843. PubMed ID: 38524877
[TBL] [Abstract] [Full Text] [Related]
3. Cardiac and Nephrological Complications Related to the Use of Antiangiogenic and Anti-Programmed Cell Death Protein 1 Receptor/Programmed Cell Death Protein 1 Ligand Therapy.
Stachyra-Strawa P; Szatkowska-Sieczek L; Cisek P; Gołębiowski P; Grzybowska-Szatkowska L
Genes (Basel); 2024 Jan; 15(2):. PubMed ID: 38397167
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence and management of proteinuria associated with vascular endothelial growth factor receptor-targeted tyrosine kinase inhibitor treatment in advanced renal cell carcinoma, hepatocellular carcinoma, and thyroid cancer.
Kato T; Mizuno R; Miyake H
Int J Urol; 2024 May; 31(5):465-474. PubMed ID: 38318663
[TBL] [Abstract] [Full Text] [Related]
5. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
6. treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
[TBL] [Abstract] [Full Text] [Related]
7. Acute heart failure following pazopanib treatment: a literature review featuring two case reports.
Kertmen N; Kavgaci G; Yildirim HC; Dizdar O
Anticancer Drugs; 2024 Mar; 35(3):302-304. PubMed ID: 38018812
[TBL] [Abstract] [Full Text] [Related]
8. [The treatment of Metastatic Renal Cell Carcinoma: An Update].
Pezzicoli G; Ganini C; Re Sartò GV; Pirovano M; Cosmai L; Porta C
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007832
[TBL] [Abstract] [Full Text] [Related]
9. Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
Schuster J; Sheng IY; Reddy CA; Khorana AA; Nizam A; Gupta S; Gilligan T; Wee CE; Sussman TA; Bonham A; Maroli K; Martin A; Ornstein MC
Clin Genitourin Cancer; 2024 Apr; 22(2):92-97. PubMed ID: 37932205
[TBL] [Abstract] [Full Text] [Related]
10. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
11. LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma.
Choueiri TK; Powles T; Voss MH; Plimack ER; Gurney H; Song Y; Perini RF; Rodriguez-Lopez K; Rini BI
Future Oncol; 2023 Dec; 19(40):2631-2640. PubMed ID: 37882432
[TBL] [Abstract] [Full Text] [Related]
12. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With vegfr TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
13. PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors.
Stokes ME; Calvo V; Fujisawa S; Dudgeon C; Huang S; Ballal N; Shen L; Gasparek J; Betzenhauser M; Taylor SJ; Staschke KA; Rigby AC; Mulvihill MJ; Bose N; Lightcap ES; Surguladze D
Clin Cancer Res; 2023 Dec; 29(23):4870-4882. PubMed ID: 37733811
[TBL] [Abstract] [Full Text] [Related]
14. Impact of First Line Antiangiogenic Therapy Duration on Nivolumab Outcome in Metastatic Renal Cell Carcinoma Patients Treated in the GETUG-AFU 26 NIVOREN.
Guilhem-Ducléon G; Dalban C; Negrier S; Gravis G; Laguerre B; Chevreau C; Oudard S; Barthelemy P; Ladoire S; Boughalem E; Borchiellini D; Linassier C; Nenan S; Flippot R; Albiges L; Goupil MG
Clin Genitourin Cancer; 2023 Dec; 21(6):643-652. PubMed ID: 37635052
[TBL] [Abstract] [Full Text] [Related]
15. LncRNA PVT1 promotes strong stemness and endothelial progenitor cell characteristics in renal carcinoma stem cells.
Wang L; Yang G; Guo P; Lv Y; Fu B; Bai Y; Xiong F; Zhao D; Li C; Zhang J; Bai S; Zeng F; Xu W
FASEB J; 2023 Sep; 37(9):e23118. PubMed ID: 37531296
[TBL] [Abstract] [Full Text] [Related]
16. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Kessler ER; Callihan E; Hu J; Eule C; Srivastava G; Kemme DJ; Iruku P; Rana V; Moore J; Schuster SR; Amirault M; Flaig TW; Lam ET
Cancer Res Commun; 2023 Jun; 3(6):1004-1012. PubMed ID: 37377613
[TBL] [Abstract] [Full Text] [Related]
17. Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy.
Barragan-Carrillo R; Govindarajan A; Rock A; Sperandio RC; Pal SK
Hematol Oncol Clin North Am; 2023 Oct; 37(5):965-976. PubMed ID: 37353376
[TBL] [Abstract] [Full Text] [Related]
18. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract] [Full Text] [Related]
19. Systemic Inflammatory Markers Predicting the Overall Survival of Patients Using Tyrosine Kinase Inhibitors in the First-line treatment of Metastatic Renal Cell Carcinoma.
Korkmaz M; Erylmaz MK
J Coll Physicians Surg Pak; 2023 Jun; 33(6):653-658. PubMed ID: 37300261
[TBL] [Abstract] [Full Text] [Related]
20. A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Rosenberg AJ; Liao CY; Karrison T; de Souza JA; Worden FP; Libao B; Krzyzanowska MK; Hayes DN; Winquist E; Saloura V; Prescott K; Villaflor VM; Seiwert TY; Schechter RB; Stadler WM; Cohen EEW; Vokes EE
Ann Oncol; 2023 Aug; 34(8):714-722. PubMed ID: 37182801
[TBL] [Abstract] [Full Text] [Related]
[Next]